A new trading day began on Monday, with Lyell Immunopharma Inc (NASDAQ: LYEL) stock price down -4.46% from the previous day of trading, before settling in for the closing price of $0.65. LYEL’s price has ranged from $0.58 to $3.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 428.28% over the last five years. Meanwhile, its annual earnings per share averaged 19.14%. With a float of $144.26 million, this company’s outstanding shares have now reached $256.56 million.
The firm has a total of 224 workers. Let’s measure their productivity. In terms of profitability, gross margin is -23680.95%, operating margin of -348844.44%, and the pretax margin is -323792.06%.
Lyell Immunopharma Inc (LYEL) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lyell Immunopharma Inc is 50.62%, while institutional ownership is 21.59%.
Lyell Immunopharma Inc (LYEL) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.14% per share during the next fiscal year.
Lyell Immunopharma Inc (NASDAQ: LYEL) Trading Performance Indicators
Here are Lyell Immunopharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 13.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3025.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.75 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc (LYEL)
Analysing the last 5-days average volume posted by the [Lyell Immunopharma Inc, LYEL], we can find that recorded value of 0.8 million was lower than the volume posted last year of 1.05 million. As of the previous 9 days, the stock’s Stochastic %D was 41.90%. Additionally, its Average True Range was 0.08.
During the past 100 days, Lyell Immunopharma Inc’s (LYEL) raw stochastic average was set at 3.79%, which indicates a significant decrease from 10.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.40% in the past 14 days, which was lower than the 106.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9493, while its 200-day Moving Average is $1.6356. Now, the first resistance to watch is $0.6457. This is followed by the second major resistance level at $0.6703. The third major resistance level sits at $0.6917. If the price goes on to break the first support level at $0.5997, it is likely to go to the next support level at $0.5783. Now, if the price goes above the second support level, the third support stands at $0.5537.
Lyell Immunopharma Inc (NASDAQ: LYEL) Key Stats
With a market capitalization of 181.52 million, the company has a total of 292,162K Shares Outstanding. Currently, annual sales are 130 K while annual income is -234,630 K. The company’s previous quarter sales were 30 K while its latest quarter income was -44,580 K.
